newsfilter
← Latest News
GlobeNewswire·

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

  • YD Bio Limited launched two chrono-nutrition formulations in Taiwan: a daytime lipid-soluble "Golden Triangle" formula & a nighttime zinc-plus-calcium formula.
  • The products were co-developed with the Taiwan Chronic Disease Healthcare Association (CDHA) & the Future Health Institute (FHI), which has over 233,000 YouTube subscribers.
  • The launch establishes a bottoms-up physician-partnership model where clinicians define formulation needs based on patient observations while YD Bio handles development & commercialization.
  • Each product carries the CDHA certification mark & an FHI recommendation, aiming to build trust through healthcare relationships rather than traditional marketing spend.
  • YD Bio views this collaboration as an initial deployment of a repeatable model intended to co-develop further formulations with additional physician partners.
  • The strategy is designed to be capital-light, generate recurring revenue, & create a foundation for future engagement with the company's regulated diagnostics & clinical services.
  • The daytime formulation is linked to a submitted review manuscript titled "Beyond Bone Health: Exploring the 'Heart-Brain-Bone' Axis Modulated by Lipid-Soluble Nutrients" currently under peer review.
  • CEO Dr. Ethan Shen stated the collaboration expands YD Bio's integrated healthcare platform connecting scientific innovation, clinical expertise, & patient needs.
  • YD Bio remains a U.S.-anchored biotechnology company focusing on DNA methylation-based cancer detection, ophthalmologic innovations, & life science commercialization.